The Effect of NAD Supplementation on Brain Vascular Health in Aging

Inclusion Criteria:

• Age ≥60 and ≤85 years of age

• Adequate hearing and visual acuity to participate in the examinations

• Ability to read and write in English

• Competence to provide informed consent.

• Mini-Mental State Exam score ≥24

Exclusion Criteria:

• Vision or hearing impairment that would impair the ability to complete studyassessments

• Active CNS disease including multiple sclerosis, uncontrolled seizures, active braincancer

• Cerebrovascular accident other than TIA within 60 days prior to Visit 0

• Major psychiatric disease, including major depression not currently controlled onmedications, alcohol or drug abuse

• Abnormal kidney function (creatinine >2mg/dL or EGFR <30mL/min) by most recent labswithin 6 months prior to Visit 0

• Elevated liver enzymes (AST and/or ALT above x2 upper limit of normal) by mostrecent labs within 6 months prior to Visit 0

• Treatment with other NAD enhancers (Nicotinamide riboside or nicotinamidemononucleotide) within 4 weeks prior to randomization.

• Any other medical condition which, in the opinion of investigator, would render thepatient inappropriate or too unstable to complete the study protocol